BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11668500)

  • 1. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.
    Yoon JH; Dammann R; Pfeifer GP
    Int J Cancer; 2001 Oct; 94(2):212-7. PubMed ID: 11668500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
    Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
    Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Dammann R; Yang G; Pfeifer GP
    Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
    Dammann R; Takahashi T; Pfeifer GP
    Oncogene; 2001 Jun; 20(27):3563-7. PubMed ID: 11429703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
    Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
    Liu L; Yoon JH; Dammann R; Pfeifer GP
    Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors.
    Horiguchi K; Tomizawa Y; Tosaka M; Ishiuchi S; Kurihara H; Mori M; Saito N
    Oncogene; 2003 Oct; 22(49):7862-5. PubMed ID: 14586413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
    Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of the RASSF1A gene in human cancers.
    Pfeifer GP; Yoon JH; Liu L; Tommasi S; Wilczynski SP; Dammann R
    Biol Chem; 2002 Jun; 383(6):907-14. PubMed ID: 12222680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
    Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
    Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
    Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
    Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.